Brief: Masonic Cancer Center At University Of Minnesota Receives FDA Clearance To Proceed With Phase 1 Clinical Trial In Solid Tumors For HCW9218

Hcw Biologics

24/01/2022 12:55

Jan 24 (Reuters) - HCW Biologics Inc  HCWB.O :
    * MASONIC CANCER CENTER AT UNIVERSITY OF MINNESOTA RECEIVES
FDA
CLEARANCE TO PROCEED WITH PHASE 1 CLINICAL TRIAL IN SOLID TUMORS
FOR HCW9218, HCW BIOLOGICS' NOVEL BIFUNCTIONAL FUSION PROTEIN

Source text for Eikon:  ID:nGNX5z5w2P 
Further company coverage:  HCWB.O 

 ((Reuters.Briefs@thomsonreuters.com;))